Please login to the form below

Not currently logged in
Email:
Password:

AZ's Crestor shown to cut heart attack risk

A study of around 18,000 patients with normal cholesterol levels has shown that AstraZeneca's statin Crestor significantly lowered the risk of cardiovascular events

A study of around 18,000 patients with normal cholesterol levels has shown that AstraZeneca's (AZ) statin Crestor significantly lowered the risk of cardiovascular events.

The trial, known as Jupiter, was a long-term, randomised, double-blind, placebo-controlled, large-scale study designed to test if Crestor decreased the risk of heart attack, stroke of other major cardiovascular events in patients with low to normal cholesterol levels but elevated hsCRP – a protein that causes inflammation of the arteries.

Patients were given 20mg of the drug per day for an average of two years. The risk of heart attack was cut by 54 per cent and the risk of stroke by 48 per cent. Total mortality was reduced by 20 per cent.

The trial showed a slight increase in physician-reported diabetes, although this was consistent with data from similar large placebo-controlled statin trials.

AstraZeneca plans to file a regulatory submission including the Jupiter data in the first half of 2009. If approved, it will begin promotional activities within the approved labelling.

In Q3 2008, the company reported sales of Crestor at $922m. This represented an increase of 23 per cent in the US and 33 per cent in the Rest of World compared with the same period last year.

Crestor has received regulatory approval in 95 countries and nearly 15 million patients have been prescribed the drug worldwide.

10th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics